MLH1 and Lynch syndrome: Variants in PMS2, MSH2, MSH6, and MLH1 [29] were identified in 0.2% (n = 4), 0.2% (n = 3), 0.2% (n = 3), and 0.1% (n = 2), respectively, with 0.7% of pancreatic cancer patients having Lynch syndrome-associated variants overall.